In Brief: Endosonics
This article was originally published in The Gray Sheet
Executive Summary
Endosonics: Receives go-ahead from FDA to market its Oracle Micro Plus family of combination percutaneous transluminal coronary angioplasty/ultrasound imaging catheters via premarket approval application supplement. Introduction in the U.S. is slated for the third quarter of 1995 with worldwide launch programs "planned prior to the end of this year," the firm states. The devices can both perform PTCA and image the lumen and artery wall. The supplement, submitted in November 1994, builds on the Pleasanton, California-based firm's September 1994 PMA for the first Oracle Micro system...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.